RA CAPITAL MANAGEMENT, LLC
13F Reported Value
ⓘ$9.4B
Holdings
85
Latest Filing
2026-03-31
Filing Quarter
Q1 2026
Portfolio Overview
RA CAPITAL MANAGEMENT, LLC disclosed 85 positions worth $9.4B in its Form 13F-HR for Q1 2026, led by $ASND (Ascendis Pharma A/S) at 24.9% of the equity portfolio, followed by $PCVX and $RYTM. During the quarter the fund opened 23 new positions and exited 9 — including a new stake in $SGP. The portfolio is most concentrated in Healthcare (99.6% of disclosed assets). All figures are sourced directly from RA CAPITAL MANAGEMENT, LLC’s Form 13F-HR filing with the SEC under CIK 1346824.
AI Fund Analysis
DiversifyingSector Allocation
AUM History
Top Equity Holdings by Value
Quarterly Activity — Q1 2026
Click any card to unlockTop Holdings
- 41.5#1,891
Quality
$2.4B10,281,496 sh - —
Quality
$666.8M11,474,599 sh - 30.3#2,364
Quality
$579.8M6,666,837 sh - —
Quality
$467.2M12,198,625 sh - —
Quality
$397.1M9,905,045 sh - —
Quality
$328.5M10,428,437 sh - —
Quality
$305.7M9,550,191 sh - —
Quality
$259.6M2,534,145 sh - 26.8
Quality
$219.2M2,611,733 sh - —
Quality
$208.4M7,692,750 sh
| Company | Quality | Value | Shares |
|---|---|---|---|
 Ascendis Pharma A/S$ASND | 41.5#1,891 | $2.4B | 10,281,496 |
 Vaxcyte, Inc.$PCVX | — | $666.8M | 11,474,599 |
 RHYTHM PHARMACEUTICALS, INC.$RYTM | 30.3#2,364 | $579.8M | 6,666,837 |
 Tyra Biosciences, Inc.$TYRA | — | $467.2M | 12,198,625 |
 Sionna Therapeutics, Inc.$SION | — | $397.1M | 9,905,045 |
 Edgewise Therapeutics, Inc.$EWTX | — | $328.5M | 10,428,437 |
 NewAmsterdam Pharma Co N.V.$NAMS | — | $305.7M | 9,550,191 |
 Nuvalent, Inc.$NUVL | — | $259.6M | 2,534,145 |
 Dianthus Therapeutics, Inc. /DE/$DNTH | 26.8 | $219.2M | 2,611,733 |
 Mineralys Therapeutics, Inc.$MLYS | — | $208.4M | 7,692,750 |
Unlock AI quality scores for every holding
32-signal composite ranking on each of RA CAPITAL MANAGEMENT, LLC's 85 positions.
Showing top 10 of 85 holdings.
Sector Allocation
Healthcare
$9.4B
Technology
$26.8M
Other
$12.7M
Full Holdings — RA CAPITAL MANAGEMENT, LLC (Q1 2026)
All 85 disclosed positions from the latest Form 13F-HR, with quarter-over-quarter share changes and 13F Pro quality scores. Sourced from SEC EDGAR.
| # | Ticker | Company | Value | Weight | QoQ | Quality |
|---|---|---|---|---|---|---|
| 1 | $ASND | Ascendis Pharma A/S | $2.4B | 24.9% | +0% | 41.5 |
| 2 | $PCVX | Vaxcyte, Inc. | $666.8M | 7.1% | +7% | — |
| 3 | $RYTM | RHYTHM PHARMACEUTICALS, INC. | $579.8M | 6.1% | +0% | 30.3 |
| 4 | $TYRA | Tyra Biosciences, Inc. | $467.2M | 5.0% | +0% | — |
| 5 | $SION | Sionna Therapeutics, Inc. | $397.1M | 4.2% | +0% | — |
| 6 | $EWTX | Edgewise Therapeutics, Inc. | $328.5M | 3.5% | +0% | — |
| 7 | $NAMS | NewAmsterdam Pharma Co N.V. | $305.7M | 3.2% | +0% | — |
| 8 | $NUVL | Nuvalent, Inc. | $259.6M | 2.8% | +35% | — |
| 9 | $DNTH | Dianthus Therapeutics, Inc. /DE/ | $219.2M | 2.3% | +62% | 26.8 |
| 10 | $MLYS | Mineralys Therapeutics, Inc. | $208.4M | 2.2% | +5% | — |
| 11 |  $SGP | SpyGlass Pharma, Inc. | $207.8M | 2.2% | NEW | — |
| 12 |  $WVE | Wave Life Sciences Ltd. | $195.6M | 2.1% | +48% | — |
| 13 |  $SEPN | Septerna, Inc. | $168.1M | 1.8% | +0% | 44.6 |
| 14 |  $IRON | Disc Medicine, Inc. | $156.7M | 1.7% | +24% | — |
| 15 |  $JANX | Janux Therapeutics, Inc. | $155.5M | 1.6% | +0% | 24.8 |
| 16 |  $BCRX | BIOCRYST PHARMACEUTICALS INC | $150.7M | 1.6% | +0% | 37.2 |
| 17 |  $BCAX | Bicara Therapeutics Inc. | $144.3M | 1.5% | +4% | — |
| 18 |  $PRAX | Praxis Precision Medicines, Inc. | $120.4M | 1.3% | +0% | — |
| 19 |  $GHRS | GH Research PLC | $107.9M | 1.1% | +0% | — |
| 20 |  $ZLAB | Zai Lab Ltd | $107.4M | 1.1% | NEW | — |
| 21 |  $TSHA | Taysha Gene Therapies, Inc. | $105.3M | 1.1% | +0% | 4.1 |
| 22 |  $VOR | Vor Biopharma Inc. | $96.4M | 1.0% | +0% | — |
| 23 |  $GERN | GERON CORP | $95.0M | 1.0% | +0% | — |
| 24 |  $SPRY | ARS Pharmaceuticals, Inc. | $87.2M | 0.9% | +0% | 29.7 |
| 25 |  $SRPT | Sarepta Therapeutics, Inc. | $84.9M | 0.9% | NEW | 41.6 |
| 26 |  $SYRE | Spyre Therapeutics, Inc. | $81.8M | 0.9% | +0% | — |
| 27 |  $EVMN | Evommune, Inc. | $80.3M | 0.8% | +1% | — |
| 28 |  $CLYM | Climb Bio, Inc. | $77.4M | 0.8% | +0% | — |
| 29 |  $SLDB | Solid Biosciences Inc. | $67.2M | 0.7% | +61% | — |
| 30 |  $ARTV | Artiva Biotherapeutics, Inc. | $63.5M | 0.7% | +0% | — |
| 31 |  $DMRA | Damora Therapeutics, Inc. | $62.1M | 0.7% | NEW | — |
| 32 |  $XNCR | Xencor Inc | $59.1M | 0.6% | NEW | 13.1 |
| 33 |  $LBRX | LB PHARMACEUTICALS INC | $54.5M | 0.6% | +0% | — |
| 34 |  $JBIO | Jade Biosciences, Inc. | $51.6M | 0.6% | +0% | — |
| 35 |  $ABOS | Acumen Pharmaceuticals, Inc. | $49.5M | 0.5% | +41% | — |
| 36 |  $FDMT | 4D Molecular Therapeutics, Inc. | $47.0M | 0.5% | -11% | 23.2 |
| 37 |  $FULC | Fulcrum Therapeutics, Inc. | $46.4M | 0.5% | +0% | — |
| 38 |  $CAPR | CAPRICOR THERAPEUTICS, INC. | $45.8M | 0.5% | +0% | — |
| 39 |  $IPSC | Century Therapeutics, Inc. | $40.1M | 0.4% | NEW | 43.5 |
| 40 |  $OLMA | Olema Pharmaceuticals, Inc. | $38.8M | 0.4% | +0% | — |
| 41 |  $LENZ | LENZ Therapeutics, Inc. | $38.2M | 0.4% | +0% | 19.6 |
| 42 |  $MNPR | Monopar Therapeutics | $36.6M | 0.4% | +0% | — |
| 43 |  $PEPG | PepGen Inc. | $35.5M | 0.4% | +0% | — |
| 44 |  $DSGN | Design Therapeutics, Inc. | $31.6M | 0.3% | +103% | — |
| 45 |  $MIRM | Mirum Pharmaceuticals, Inc. | $29.4M | 0.3% | NEW | 32.7 |
| 46 |  $BIOA | BioAge Labs, Inc. | $28.9M | 0.3% | NEW | 28.6 |
| 47 |  $LXEO | Lexeo Therapeutics, Inc. | $28.7M | 0.3% | +0% | — |
| 48 |  $ASMB | ASSEMBLY BIOSCIENCES, INC. | $28.3M | 0.3% | +0% | 26.6 |
| 49 |  $RZLT | Rezolute, Inc. | $28.0M | 0.3% | +0% | — |
| 50 |  $AKTS | Aktis Oncology, Inc. | $26.9M | 0.3% | NEW | — |
| 51 |  $ALXO | ALX ONCOLOGY HOLDINGS INC | $26.1M | 0.3% | NEW | — |
| 52 |  $ACRS | Aclaris Therapeutics, Inc. | $25.5M | 0.3% | NEW | 9.2 |
| 53 |  $OVID | Ovid Therapeutics Inc. | $23.8M | 0.3% | +0% | 13.1 |
| 54 |  $NKTX | Nkarta, Inc. | $22.8M | 0.2% | +0% | — |
| 55 |  $TVTX | Travere Therapeutics, Inc. | $22.2M | 0.2% | NEW | 39.2 |
| 56 |  $GRAL | GRAIL, Inc. | $22.1M | 0.2% | +0% | 31.9 |
| 57 |  $CCCC | C4 Therapeutics, Inc. | $21.0M | 0.2% | +0% | 6.5 |
| 58 |  $RLMD | RELMADA THERAPEUTICS, INC. | $20.5M | 0.2% | NEW | — |
| 59 |  $BNTC | Benitec Biopharma Inc. | $19.7M | 0.2% | +0% | — |
| 60 |  $DRUG | BRIGHT MINDS BIOSCIENCES INC. | $19.3M | 0.2% | NEW | — |
| 61 |  $STRO | SUTRO BIOPHARMA, INC. | $17.8M | 0.2% | NEW | 30.1 |
| 62 |  $CTNM | Contineum Therapeutics, Inc. | $16.9M | 0.2% | -41% | — |
| 63 |  $SABS | SAB Biotherapeutics, Inc. | $16.9M | 0.2% | +0% | — |
| 64 |  $INSP | Inspire Medical Systems, Inc. | $16.8M | 0.2% | +129% | 46 |
| 65 |  $AVR | Anteris Technologies Global Corp. | $16.6M | 0.2% | NEW | — |
| 66 |  $OKUR | OnKure Therapeutics, Inc. | $16.6M | 0.2% | NEW | — |
| 67 |  $HNGE | Hinge Health, Inc. | $14.1M | 0.1% | +355% | 44.9 |
| 68 |  $WGS | GeneDx Holdings Corp. | $13.5M | 0.1% | +262% | 38.6 |
| 69 |  $WAY | Waystar Holding Corp. | $12.8M | 0.1% | +267% | 71.4 |
| 70 | — | HELIX ACQUISITION CORP-CL A | $12.7M | 0.1% | NEW | — |
| 71 |  $PALI | PALISADE BIO, INC. | $12.5M | 0.1% | +0% | — |
| 72 |  $ACRV | Acrivon Therapeutics, Inc. | $11.6M | 0.1% | +0% | — |
| 73 |  $RNA | Avidity Biosciences, Inc. | $11.6M | 0.1% | -90% | 22.3 |
| 74 |  $KPTI | Karyopharm Therapeutics Inc. | $10.7M | 0.1% | NEW | 20.4 |
| 75 |  $AVTX | Avalo Therapeutics, Inc. | $9.9M | 0.1% | +0% | 4.6 |
| 76 |  $PCSC | Perceptive Capital Solutions Corp | $8.2M | 0.1% | +0% | — |
| 77 |  $ACET | Adicet Bio, Inc. | $8.1M | 0.1% | +25% | — |
| 78 | $NAMS | NewAmsterdam Pharma Co N.V. | $6.7M | 0.1% | +0% | — |
| 79 |  $CRVS | Corvus Pharmaceuticals, Inc. | $6.6M | 0.1% | NEW | — |
| 80 |  $RANI | Rani Therapeutics Holdings, Inc. | $6.2M | 0.1% | +0% | — |
| 81 |  $EQ | Equillium, Inc. | $6.2M | 0.1% | NEW | 27.2 |
| 82 |  $HOWL | Werewolf Therapeutics, Inc. | $5.6M | 0.1% | +0% | — |
| 83 |  $MGNX | MACROGENICS INC | $5.4M | 0.1% | NEW | 31.7 |
| 84 |  $MPLT | MapLight Therapeutics, Inc. | $5.0M | 0.1% | NEW | — |
| 85 |  $PTN | PALATIN TECHNOLOGIES INC | $1.2M | 0.0% | +0% | — |
New Positions (23)
$SGP SpyGlass Pharma, Inc.$207.8M$ZLAB Zai Lab Ltd$107.4M$SRPT Sarepta Therapeutics, Inc.$84.9M$DMRA Damora Therapeutics, Inc.$62.1M$XNCR Xencor Inc$59.1M$IPSC Century Therapeutics, Inc.$40.1M$MIRM Mirum Pharmaceuticals, Inc.$29.4M$BIOA BioAge Labs, Inc.$28.9M$AKTS Aktis Oncology, Inc.$26.9M$ALXO ALX ONCOLOGY HOLDINGS INC$26.1M$ACRS Aclaris Therapeutics, Inc.$25.5M$TVTX Travere Therapeutics, Inc.$22.2M$RLMD RELMADA THERAPEUTICS, INC.$20.5M$DRUG BRIGHT MINDS BIOSCIENCES INC.$19.3M$STRO SUTRO BIOPHARMA, INC.$17.8M
Browse Top Institutional Investors
13F Pro tracks 8,700+ institutional investors filing 13F reports with the SEC.
to search all 8,700+ institutional filers.
Available Analysis
13F Pro tracks comprehensive institutional data for RA CAPITAL MANAGEMENT, LLC including:
Track RA CAPITAL MANAGEMENT, LLC's Full Portfolio
See every holding, quarter-over-quarter changes, sector allocation, and accumulation patterns for RA CAPITAL MANAGEMENT, LLC and 8,700+ other institutional investors.
Free tier includes full 13F search and fund profiles. Pro starts at $6.67/mo (billed annually).
AI-Powered Hedge Fund Analysis: RA CAPITAL MANAGEMENT, LLC
13F Pro is an AI hedge fund tracker and stock research platform. For RA CAPITAL MANAGEMENT, LLC (SEC CIK: 1346824), the platform ingests every quarterly Form 13F filing and applies AI-powered analysis on top — 10 specialized AI analysts (value, growth, momentum, macro, activist, and more) debate the fund's top positions and publish AI-generated analysis with cited SEC sources.
Every holding in RA CAPITAL MANAGEMENT, LLC's portfolio is scored on a 32-signal AI quality ranking (ROIC, FCF margin, revenue growth, institutional flow, earnings quality, shareholder dilution, and more). Track accumulation and distribution quarter over quarter, identify conviction positions, and see AI stock analysis for each position — alongside 8,700+ other institutional filers and 2,800+ AI-ranked companies.